NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

GeneDx Holdings Corp. (WGS) Stock Analysis

GeneDx Holdings Corp. (WGS) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

WGS

$68.94

+$0.20 (+0.29%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WGS with… →

WGS Key Statistics

As of Oct 21, 2026
Trading
Open
$69.16
Previous Close
$68.74
Day's Range
68.25–71.53
52-Week Range
32.21–170.87
Volume
832.72K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.97
Valuation
Market Cap
$2.06B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
57.52
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.52
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.63
Financials (FY)
Revenue (FY)
$427.54M+39.97%
Net Income (FY)
−$21.02M
Profit marginThe share of revenue left as profit after all costs and taxes.
−23.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.82M
1-Year Return
−43.39%
Dividend and dates
Earnings Date
October 27, 2026estimated
Avg Volume
723.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, WGS closed at $68.94, −43.39% over 1 year.

GeneDx Holdings Corp. (WGS) has a market capitalization of $2.06B.

In fiscal 2025, WGS reported revenue of $427.54M.

WGS Stock Return by Calendar Year

GeneDx Holdings Corp. (WGS) return since Nov 2020: what $10,000 became

1 year
$10,000 $5,661
−43.39%
5 years
$10,000 $2,800
−72.00%
Since Nov 2020
$10,000 $2,132
−78.68%

If you had invested $10,000 in GeneDx Holdings Corp. (WGS) at the close on November 4, 2020, the earliest close on record here, it would have been worth $2,132 at the close on October 21, 2026: −78.68% in total, −22.84% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.99%
2025+69.22%
2024+2,694.91%
2023−68.43%
2022−94.08%
2021−59.60%
2020 (partial year)+12.65%

As of October 21, 2026.

WGS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$427.54M−$21.02M−4.9%
2024$305.45M−$52.29M−17.1%
2023$202.57M−$175.77M−86.8%
2022$234.69M−$548.98M−233.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$427.54M$298.17M−$13.08M−$21.02M−4.9%
2024$305.45M$194.40M−$23.21M−$52.29M−17.1%
2023$202.57M$90.01M−$170.19M−$175.77M−86.8%
2022$234.69M−$26.75M−$457.51M−$548.98M−233.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WGS Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricWGSDiagnostics & Research medianvs median
P/S ratio4.525.2313% below
Profit margin−23.41%−0.93%22.5 pts below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values GeneDx Holdings Corp. (WGS) at $2.06B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 1,300 employees.

The most recent close on file for WGS is $68.94, dated October 21, 2026. That is +$0.20 (+0.29%) against the previous close. The 52-week range on file runs from $32.21 to $170.87. The latest close sits 114.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $427.54M. That is +39.97% against the prior fiscal year, when revenue was $305.45M. The same year closed with a net loss of $21.02M. The reported profit margin is −23.41%. That is 22.5 percentage points below the Diagnostics & Research median of −0.93%. Earnings per share on a trailing basis come to −3.63.

Across the 4 fiscal years on file, revenue moves from $234.69M in 2022 to $427.54M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 57.52. Measured against sales, the shares trade at 4.52 times revenue. On price-to-sales that is 13.44% below the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −43.39%. Measured over 5 years, that is −22.47% a year compounded. Beta against the wider market is reported at 1.97. Annualized volatility over the trailing 6 years is 105.61%.

Growth & Income

The record shows no dividend for WGS.

The strongest complete calendar year on file is 2024 at +2,694.91%; the weakest is 2022 at −94.08%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −46.99%.

Peer Comparison

GeneDx Holdings Corp. (WGS) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GeneDx Holdings Corp. WGS $2.06B —
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. GeneDx Holdings Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About GeneDx Holdings Corp.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Visit website →